Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
Krystal Biotech price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Krystal Biotech's price to sales ratio was 20.7× on Nov 11, 2026, against 16.9× a year earlier. Over the last 3 years it ranged from 10.9× to 408.8×, with a median of 21.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 20.7× | +1.6 |
| 2025 | Dec 31, 2025 | 19.1× | +0.5 |
| 2024 | Dec 31, 2024 | 18.7× | −390.2 |
| 2023 | Dec 29, 2023 | 408.8× | – |
See a number that looks wrong?